CytomX Therapeutics (CTMX)
(Delayed Data from NSDQ)
$1.19 USD
+0.04 (3.48%)
Updated Sep 24, 2024 04:00 PM ET
After-Market: $1.20 +0.01 (0.84%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth B Momentum F VGM
Average Brokerage Rating
Current ABR | 1.86 |
ABR (Last week) | 1.86 |
# of Recs in ABR | 7 |
Average Target Price | $5.77 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 80 of 253 |
Current Quarter EPS Est: | -0.12 |
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 4 | 4 | 4 | 4 | 4 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 3 | 3 | 3 | 3 | 3 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.86 | 1.86 | 1.86 | 1.86 | 1.86 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/22/2024 | H.C. Wainwright & Co. | Mitchell S Kapoor | Hold | Hold |
5/9/2024 | Wedbush Securities | Robert Driscoll | Hold | Strong Buy |
5/9/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
5/6/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
3/12/2024 | BMO Capital Markets | Etzer Darout | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.